AGAlf Grandien

Alf Grandien

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alf Grandien has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Kari Högstrand

    Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden

    4 shared publications
  • Aimé Vázquez

    United States Department of Agriculture-Agricultural Research Service (USDA-ARS), Subtropical Horticulture Research Station (SHRS), Miami, FL 33158, USA

    1 shared publication
  • Anne Sundblad

    Hematology Center, CMM, Bioclinicum, Department of Medicine, Karolinska Institutet, Karolinska University Hospital - Solna, Solna, Sweden

    1 shared publication
  • Birgitta Sander

    Divisions of Clinical Research Center and Pathology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    1 shared publication
  • Björn Rozell

    Divisions of Clinical Research Center and Pathology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    1 shared publication
  • Boris Zhivotovsky

    Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

    1 shared publication

Latest Publications

  • Open Access

    Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements

    by Kari Högstrand, Jessica M. Lindvall, Anne Sundblad, Alf Grandien

    An experimental system where defined alterations in gene function or gene expression levels in primary B cells would result in the development of transformed plasma cells in vitro would be useful in order to facilitate studies of the underlying molecular mechanisms of plasma cell malignancies. Here, such a system is described in which primary murine B cells rapidly become transformed into surface CD138+, IgM−/low, CD19− IgM‐secreting plasma cells as a result of expression of the transcription factors IRF4 and MYC together with simultaneous expression of BMI1, mutated p53 or silencing of p19Arf, and suppression of intrinsic apoptosis through expression of BCLXL. Analysis of gene expression patterns revealed that this combination of transforming genes resulted in expression of a number of genes previously associated with terminally differentiated B cells (plasma cells) and myeloma cells, whereas many genes associated with mature B cells and B‐cell lymphomas were not expressed. Upon transplantation, the transformed cells preferentially localized to the bone marrow, presenting features of a plasma cell malignancy of the IgM isotype. The present findings may also be applicable in the development of novel methods for production of monoclonal antibodies.


  • MYC‐driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity

    by Kari Högstrand, Alf Grandien

    Increased expression of the oncogene MYC is a common feature of many B‐cell malignancies, however MYC overexpression by itself is not sufficient for transformation, and additional genetic events are required, although the exact nature of these remains unknown. In patients and in transgenic mouse models, oncogenic transformation may occur in B cells at various differentiation stages interacting with complex microenvironments. B‐cell oncogenesis often occurs after prolonged periods of time, making it difficult to accurately identify the genetic events required for transformation. An in vitro system, where malignant transformation of primary B cells could be analyzed, would facilitate the identification of genetic events required for transformation. Here, we describe such a system and show that primary murine B cells rapidly become transformed upon forced expression of MYC, in conjunction with simultaneous inhibition of the ARF/p53 axis via overexpression of BMI1, as well as through downregulation of p19ARF or expression of a dominant‐negative p53 and suppression of intrinsic apoptosis through overexpression of BCLXL or MCL1. Established tumor cells remained addicted to expression of the lymphoma‐inducing genes. In mice, transformed cells rapidly established fatal B‐cell lymphomas.Our results suggest that transformation of normal mature B cells into lymphomas can occur as a consequence of three defined events.


  • Open Access

    Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis

    by Kari Högstrand, Stephanie Darmanin, TachaZi Plym Forshell, Alf Grandien

    Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis


  • Open Access

    Inhibition of the Intrinsic but Not the Extrinsic Apoptosis Pathway Accelerates and Drives Myc-Driven Tumorigenesis Towards Acute Myeloid Leukemia

    by Kari Högstrand, Eduar Hejll, Birgitta Sander, Björn Rozell, Lars-Gunnar Larsson, Alf Grandien

    Myc plays an important role in tumor development, including acute myeloid leukemia (AML). However, MYC is also a powerful inducer of apoptosis, which is one of the major failsafe programs to prevent cancer development. To clarify the relative importance of the extrinsic (death receptor-mediated) versus the intrinsic (mitochondrial) pathway of apoptosis in MYC-driven AML, we coexpressed MYC together with anti-apoptotic proteins of relevance for AML; BCL-XL/BCL-2 (inhibiting the intrinsic pathway) or FLIPL (inhibiting the extrinsic pathway), in hematopoietic stems cells (HSCs). Transplantation of HSCs expressing MYC into syngeneic recipient mice resulted in development of AML and T-cell lymphomas within 7–9 weeks as expected. Importantly, coexpression of MYC together with BCL-XL/BCL-2 resulted in strongly accelerated kinetics and favored tumor development towards aggressive AML. In contrast, coexpression of MYC and FLIPL did neither accelerate tumorigenesis nor change the ratio of AML versus T-cell lymphoma. However, a change in distribution of immature CD4+CD8+ versus mature CD4+ T-cell lymphoma was observed in MYC/FLIPL mice, possibly as a result of increased survival of the CD4+ population, but this did not significantly affect the outcome of the disease. In conclusion, our findings provide direct evidence that BCL-XL and BCL-2 but not FLIPL acts in synergy with MYC to drive AML development.


  • Open Access

    Participation of FLIP, RIP and Bcl-xLin Fas-mediated T-cell Death

    by M. Djerbi, M. M. Malinowski, H. Yagita, B. Zhivotovsky, A. Grandien

    Apart from the conventional Fas signalling pathway, alternative pathways including the mitochondrial caspase‐dependent and RIP‐mediated cell death routes have been proposed to operate during Fas‐mediated cell death. To evaluate the contribution of different Fas signalling pathways, mice overexpressing FLIPL, Bcl‐xL, a kinase‐deficient form of RIP (RIPΔkin) or combinations thereof were generated by retroviral gene transfer of haematopoietic stem cells. Such mice did not show overt abnormalities in haematopoietic development, defects in thymic deletion, accumulation of double‐negative T cells or signs of autoimmunity. Fas‐mediated death of mitogen‐activated T cells was caspase dependent and could be blocked by FLIPL overexpression only with the minor involvement of Bcl‐xL or RIPΔkin inhibitable pathways. Fas‐mediated death of resting CD4+ and CD8+ T cells was mainly caspase dependent but could only partly be blocked by FLIPL overexpression. Both Bcl‐xL or RIPΔkin expression resulted in partial protection of CD8+ T cells against Fas‐mediated cell death. These results indicate that yet uncharacterized signalling pathways from the Fas receptor are critically involved in lymphoproliferative and autoimmune disease observed in lpr mice and autoimmune lymphoproliferative syndrome patients.


  • Open Access

    Expression of a V Region-Less B Cell Receptor Confers a Tolerance-Like Phenotype on Transgenic B Cells

    by Daniel Corcos, Alf Grandien, Aimé Vazquez, Olga Dunda, Patrick Lorès, Danielle Bucchini

    Neoplastic B cells from H chain disease patients express a truncated B cell receptor (BCR), comprising a membrane Ig that lacks part of its extracellular domain. It has been speculated that deletion of the Ag binding domain would confer a constitutive activity on the BCR, as it has been shown for oncogenic growth factor receptors. A V region-less BCR has constitutive activity, because in transgenic mice it causes inhibition of endogenous H chain gene rearrangements and relieves the requirement for surrogate L chain in pre-B cell development. However, it has been speculated that normal Ag receptors also display constitutive activity. Here we show that transgenic B cells expressing a membrane H chain disease protein on their surface are phenotypically and functionally similar to B cells developing in the presence of their cognate Ag and that cells with normal levels of mutant BCR are eliminated in spleen via a bcl-2 sensitive pathway while progressing toward the mature stage. In contrast, cells with lower levels of mutant receptors develop as mature B cells. These findings support the view that the truncated BCR has a constitutive activity that mimics ligand binding, in analogy to what has been shown for oncogenic growth factor receptors.